FDA delays decision on Belite Bio’s eye disease drug
The FDA has extended its review of Belite Bio’s experimental eye disease drug tinlarebant by three months, moving its decision deadline to May 12, 2027. The agency needs additional time to evaluate information supporting the drug’s application for Stargardt disease type 1, an inherited retinal disorder, according to a Nov. 20 news release.  If the […] The post FDA delays decision on Belite Bio’s eye disease drug appeared first on Becker's Hospital Review | Healt...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.